--- title: "NovaBridge Biosciences Executive Begins Open-Market ADS Purchases" description: "NovaBridge Biosciences announced that Dr. Sean Cao, Chief Business Development Officer, has started purchasing up to $100,000 of the company's American depositary shares (ADSs) in the open market. Thi" type: "news" locale: "en" url: "https://longbridge.com/en/news/273372934.md" published_at: "2026-01-22T12:32:40.000Z" --- # NovaBridge Biosciences Executive Begins Open-Market ADS Purchases > NovaBridge Biosciences announced that Dr. Sean Cao, Chief Business Development Officer, has started purchasing up to $100,000 of the company's American depositary shares (ADSs) in the open market. This insider buying indicates confidence in the company's prospects as it develops drug candidates like givastomig and ragistomig. However, the company warns of clinical and financial risks. The latest analyst rating for NBP stock is a Hold with a $3.50 price target, and Spark's AI Analyst rates it as Neutral due to deteriorating financial performance and bearish technicals. ### Claim 50% Off TipRanks Premium - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential NovaBridge Biosciences ( (NBP) ) has provided an announcement. On January 21, 2026, NovaBridge Biosciences announced that its Chief Business Development Officer and board member, Dr. Sean Cao, has begun purchasing the company’s American depositary shares in the open market, with plans to buy up to $100,000 of ADSs, although the exact number of shares and timeline for these transactions remain uncertain. The insider buying by a senior executive signals internal confidence in NovaBridge’s prospects as it advances a pipeline of drug candidates including givastomig, ragistomig, uliledlimab and VIS-101, but the company cautions that its progress remains subject to clinical, regulatory, market and financing risks outlined in its U.S. securities filings. The most recent analyst rating on (NBP) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on NovaBridge Biosciences stock, see the NBP Stock Forecast page. **Spark’s Take on NBP Stock** According to Spark, TipRanks’ AI Analyst, NBP is a Neutral. The score is primarily held back by deteriorated financial performance (no 2024 revenue, persistent losses, and ongoing cash burn) despite low leverage. Technicals are mildly bearish with price below key moving averages and a slightly negative MACD, while valuation is largely neutral because negative earnings make the P/E less informative and no dividend support is shown. To see Spark’s full report on NBP stock, click here. **More about NovaBridge Biosciences** NovaBridge Biosciences is a foreign private issuer in the biotechnology and biopharmaceutical sector, focused on developing innovative drug candidates including monoclonal antibody and immuno-oncology therapies such as givastomig, ragistomig, uliledlimab and VIS-101. The company is listed in the United States via American depositary shares (ADSs) and targets global markets for novel therapeutics, while relying on external partners for aspects of drug development, manufacturing and related services. **Average Trading Volume:** 749,440 **Technical Sentiment Signal:** Buy **Current Market Cap:** $451.9M For an in-depth examination of NBP stock, go to TipRanks’ Overview page. ### Related Stocks - [NBP.US - NovaBridge Biosciences](https://longbridge.com/en/quote/NBP.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | NovaBridge Biosciences (NASDAQ:NBP) Shares Could Be 41% Below Their Intrinsic Value Estimate | NovaBridge Biosciences (NASDAQ:NBP) is estimated to be 41% undervalued, with a fair value of US$6.72 compared to the cur | [Link](https://longbridge.com/en/news/271236079.md) | | Indiqube Spaces Says Promoter Group May Purchase Equity Shares From Open Market | Indiqube Spaces Ltd :INDIQUBE SPACES LTD - PROMOTER GROUP MAY PURCHASE EQUITY SHARES FROM OPEN MARKET | [Link](https://longbridge.com/en/news/276043643.md) | | Regeneron Pharmaceuticals Says its FOP Drug Candidate Garetosmab's BLA Gets US FDA Priority Review | Regeneron Pharmaceuticals Says its FOP Drug Candidate Garetosmab's BLA Gets US FDA Priority Review | [Link](https://longbridge.com/en/news/276347663.md) | | Infleqtion makes its trading debut. Another quantum stock is in the public market | The company’s technology centers on particles that are cooled to near absolute zero and controlled by lasers. | [Link](https://longbridge.com/en/news/276161985.md) | | FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals | FDA Commissioner Marty Makary warned that the U.S. is losing its competitive edge in early drug development to China. He | [Link](https://longbridge.com/en/news/276268124.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.